PL3661941T3 - Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego - Google Patents

Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego

Info

Publication number
PL3661941T3
PL3661941T3 PL18733649.0T PL18733649T PL3661941T3 PL 3661941 T3 PL3661941 T3 PL 3661941T3 PL 18733649 T PL18733649 T PL 18733649T PL 3661941 T3 PL3661941 T3 PL 3661941T3
Authority
PL
Poland
Prior art keywords
receptor antagonists
adenosine receptor
thiazolopyridine derivatives
thiazolopyridine
derivatives
Prior art date
Application number
PL18733649.0T
Other languages
English (en)
Inventor
Eva-Maria TANZER
Kai Schiemann
Markus Klein
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL3661941T3 publication Critical patent/PL3661941T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
PL18733649.0T 2017-08-01 2018-07-02 Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego PL3661941T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17184272 2017-08-01
PCT/EP2018/067797 WO2019025099A1 (en) 2017-08-01 2018-07-02 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
PL3661941T3 true PL3661941T3 (pl) 2023-05-08

Family

ID=59506176

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18733649.0T PL3661941T3 (pl) 2017-08-01 2018-07-02 Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego

Country Status (24)

Country Link
US (1) US11186592B2 (pl)
EP (1) EP3661941B1 (pl)
JP (1) JP7336434B2 (pl)
KR (1) KR102717280B1 (pl)
CN (1) CN110997681B (pl)
AU (1) AU2018309265B2 (pl)
BR (1) BR112020001978A2 (pl)
CA (1) CA3071575A1 (pl)
DK (1) DK3661941T3 (pl)
ES (1) ES2940407T3 (pl)
FI (1) FI3661941T3 (pl)
HR (1) HRP20230251T1 (pl)
HU (1) HUE061308T2 (pl)
IL (1) IL272284B2 (pl)
LT (1) LT3661941T (pl)
NZ (1) NZ760516A (pl)
PL (1) PL3661941T3 (pl)
PT (1) PT3661941T (pl)
RS (1) RS64035B1 (pl)
SG (1) SG11202000823WA (pl)
SI (1) SI3661941T1 (pl)
TW (1) TWI850199B (pl)
WO (1) WO2019025099A1 (pl)
ZA (1) ZA202001295B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CN112174943A (zh) * 2019-07-03 2021-01-05 四川大学 一种吲哚-2-酮类化合物在制备防治口腔细菌产品中的用途
CA3220380A1 (en) 2021-06-07 2022-12-15 Rinat ZAYNAGETDINOV Combination treatment of cancer
KR20250048043A (ko) 2022-08-02 2025-04-07 메르크 파텐트 게엠베하 (S)-7-옥사-2-아자-스피로[4.5]데칸-2-카르복실산 [7-(3,6-디히드로-2H-피란-4-일)-4-메톡시-티아졸로[4,5-c]피리딘-2-일]-아미드의 신규의 결정질 형태 및 이의 공-결정 형태

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CN1125817C (zh) 1996-02-13 2003-10-29 曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド 4―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6579868B1 (en) 1998-01-05 2003-06-17 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ516260A (en) 1999-07-02 2004-08-27 Eisai Co Ltd Fused imidazole compounds and remedies for diabetes mellitus
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
EP1797878A3 (en) * 2000-06-21 2010-01-20 F. Hoffmann-La Roche AG Benzothiazole derivatives
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
WO2004092171A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
RU2351597C2 (ru) * 2003-05-19 2009-04-10 Ф.Хоффманн-Ля Рош Аг Производные бензотиазола в качестве лигандов аденозиновых рецепторов
AU2004274154A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
RU2382782C2 (ru) 2004-07-22 2010-02-27 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
CA2651769C (en) * 2006-05-18 2013-12-17 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
DK3661941T3 (da) 2023-03-13
TW201920201A (zh) 2019-06-01
EP3661941B1 (en) 2022-12-14
FI3661941T3 (fi) 2023-03-23
NZ760516A (en) 2026-01-30
KR20200035439A (ko) 2020-04-03
HUE061308T2 (hu) 2023-06-28
US11186592B2 (en) 2021-11-30
TWI850199B (zh) 2024-08-01
KR102717280B1 (ko) 2024-10-14
SG11202000823WA (en) 2020-02-27
ES2940407T3 (es) 2023-05-08
JP2020528922A (ja) 2020-10-01
RU2020107737A3 (pl) 2021-11-23
LT3661941T (lt) 2023-04-11
ZA202001295B (en) 2023-09-27
IL272284B2 (en) 2024-01-01
PT3661941T (pt) 2023-03-16
EP3661941A1 (en) 2020-06-10
CA3071575A1 (en) 2019-02-07
HRP20230251T1 (hr) 2023-04-14
IL272284A (en) 2020-03-31
CN110997681A (zh) 2020-04-10
RS64035B1 (sr) 2023-04-28
US20200181171A1 (en) 2020-06-11
AU2018309265A1 (en) 2020-03-19
IL272284B1 (en) 2023-09-01
AU2018309265B2 (en) 2022-06-02
RU2020107737A (ru) 2021-09-02
WO2019025099A1 (en) 2019-02-07
SI3661941T1 (sl) 2023-04-28
CN110997681B (zh) 2022-11-15
JP7336434B2 (ja) 2023-08-31
BR112020001978A2 (pt) 2020-08-18

Similar Documents

Publication Publication Date Title
HUE056634T2 (hu) Rákellenes szerekként hasznos szubsztituált karbonukleozid-származékok
PL3897842T3 (pl) Pochodne bicykliczne
DK3368060T3 (da) Glugacon-receptor-agonister
DK3319956T3 (da) Substituerede oxopyridinderivater
PL3283110T3 (pl) Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
EP3521427A4 (en) CO-RECEPTOR OF A FRAGRANCE RECEPTOR
ES1243880Y (es) Cepillo de dientes
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
IL265166B (en) Anti-influenza virus pyrimidine derivatives
PT3264956T (pt) Conjunto de taça
PT3515887T (pt) Antagonistas de trpv4
SG11202001337XA (en) Bezimidazole derivatives as adenosine receptor antagonists
DK3672951T3 (da) Quinoxalinderivater som adenosinreceptorantagonister
EP3437776A4 (en) CONNECTION STRUCTURE
DK3713928T3 (da) Hidtil ukendte bradykinin-b2-receptorantagonister
PT3625224T (pt) Derivados de indol n-substituídos
LT3914600T (lt) Tiazolopiridino dariniai kaip adenozino receptoriaus antagonistai
EP3663026A4 (en) Lathe
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
DK3652176T3 (da) Substituerede xanthinderivater
PL3661941T3 (pl) Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego
EP3609868A4 (en) TETRAHYDROQUINOLEIN DERIVATIVES USED AS P2X7 RECEPTOR ANTAGONISTS
PT3796975T (pt) Derivados de sulfonilaminobenzamida
DK3645513T3 (da) Benzazepinderivater
EP3584023A4 (en) HORIZONTAL TOWER